Sertraline Compared With Hypericum Perforatum (St.John's Wort) in Treating Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-03-01

Study Completion Date

2005-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Antidepressants such as sertraline and the herb hypericum perforatum (St. John's wort) may be effective in treating mild to moderate depression. It is not yet known which treatment is more effective in improving depression in patients who have cancer.

PURPOSE: This randomized phase III trial is studying how well sertraline works compared to St. John's wort in treating mild to moderate depression in patients with solid tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Major Depression With St. John's Wort (Hypericum)

NCT00005013

Major Depression

COMPLETED NA

Low Dose St John's Wort for Depression

NCT05477472

Major Depression

COMPLETED

Neuroimaging of St. John's Wort-Induced Changes of Serotonin Metabolism in Normal Subjects

NCT00001919

Healthy Mood Disorder

COMPLETED

Rhodiola Rosea Therapy of Major Depressive Disorder

NCT01098318

Depression

COMPLETED PHASE3

Drug Therapy to Treat Minor Depression

NCT00048815

Depression

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Compare the change in depression severity in cancer patients with mild to moderate depression treated with sertraline vs Hypericum perforatum.
* Compare the severity of somnolence, nausea, and insomnia in patients treated with these regimens.
* Compare the impact of these regimens on fatigue in these patients.
* Correlate hyperforin concentrations with change in depression severity in patients treated with Hypericum perforatum.

OUTLINE: This is a randomized, double-blind study. Patients are stratified according to level of depression (mild vs moderate), concurrent radiotherapy (yes vs no), and TNM stage (I, II, or III vs IV). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive oral sertraline daily.
* Arm II: Patients receive oral Hypericum perforatum daily. In both arms, treatment continues for 4 months in the absence of unacceptable toxicity.

Measurements of depression, somnolence, nausea, insomnia, fatigue, and hyperforin concentration are assessed at baseline, and at 1, 2, and 4 months.

PROJECTED ACCRUAL: A maximum of 250 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression Unspecified Adult Solid Tumor, Protocol Specific

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1: Sertraline (Zoloft) 50 mg

Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months

Group Type ACTIVE_COMPARATOR

Zoloft 50 mg

Intervention Type DRUG

Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months

Arm 2 - St. John's Wort 600mg

St. John's wort 600 mg daily for 1 week. If tolerated dose may be increased to 900 mg daily for four months.

Group Type ACTIVE_COMPARATOR

St. John's Wort 600 mg

Intervention Type DIETARY_SUPPLEMENT

St. John's wort 600 mg daily for 1 week, if tolerated. Dose may be increased to 900 mg daily for 4 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zoloft 50 mg

Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months

Intervention Type DRUG

St. John's Wort 600 mg

St. John's wort 600 mg daily for 1 week, if tolerated. Dose may be increased to 900 mg daily for 4 months.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sertraline Zoloft Hypericum perforatum

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mild or moderate depression as determined by the following criteria (see Section 7.1 and 8.0)
* Mild : HRSD score 10-14; moderate: HRSD score 15-19 (Appendix IV)
* At least 2 of nine symptoms of depression on the PHQ (Appendix V)
* At least one of the nine PHQ symptoms must be either depressed/irritable mood or anhedonia
* Histologically or cytologically documented solid tumor, lymphoma, or primary or metastatic brain tumor \> 6 months from radiation with stable disease or no evidence of disease.
* Concurrent cancer chemotherapy with sertraline or St. John's wort is not allowed, therefore patients must have no plan for chemotherapy for 4 months
* Prior chemotherapy is allowed, but patients must be \>4 weeks from prior chemotherapy except \>6 weeks from prior mitomycin-C or nitrosourea
* Patients receiving Rituxin, Herceptin, Erbitux, Interferon, etc. are eligibile for this study while under treatment.
* Prior or concurrent radiation is allowed except brain irradiation for brain metastases or primary brain tumor. Must be \> 6 months from radiation with stable disease or no evidence of disease.
* Age \> 18 years
* ECOG performance status 0 -1 (Appendix III)
* Life expectancy \>4 months
* Required initial laboratory values (within 3 days of registration): hemoglobin \>10 g/dl and bilirubin \<1.5 mg/dl, negative pregnancy test
* Signed protocol specific informed consent prior to registration
* Patient recruitment this study will be done through the out patient clinic. The research PI or designee including clinic physician, resident, research nurse or research assistant will review medical information to determine or verify protocol eligibility either at the time the patient is being seen in the clinic for a routine visit/consult or prior to the patient's clinic visit.

Exclusion Criteria

* A patient will be excluded if he/she is (a) judged to be severely depressed using the following criteria: HRSD score 20 or more or a positive score on PHQ item i (suicidal ideation) or (b) judged not to be depressed by a score of 9 or less on the HRSD or fewer than two PHQ items scored positively. A patient who is found to be severely depressed or suicidal, either on initial screening or during the trial will be referred for appropriate treatment.
* Psychotic symptoms, dementia, marked agitation requiring medication
* Current or previous alcohol or drug dependence
* Hematologic malignancy (i.e., leukemias, multiple myeloma)
* Planned chemotherapy in the next 4 months
* Antidepressant or St. John's wort use in the last 4 weeks
* Current or planned use of erythropoietin (Procrit®, Aranesp®)
* Current or planned use of theophylline, warfarin (except for central line prophylaxis), protease inhibitors used to treat AIDS, digoxin, cyclosporin, benzodiazepines (such as diazepam, alprazolam, etc), calcium-channel blockers (such as diltiazem, nifedipine, etc), coenzyme A reductase inhibitors (cholesterol lowering agents), macrolide antibiotics (such as azithromycin, erythromycin, clarithromycin, etc), griseofulvin, phenobarbital, phenytoin, rifampin, rifabutin, ketoconazole, fluconazole, itraconazole, corticosteroids, grapefruit juice, or other naturopathic/herbal products that could interfere with St. John's wort (call study chairman with questions).
* Pregnant or nursing women

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No